160 related articles for article (PubMed ID: 35130506)
1. T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy.
Kumar-Sinha C; Sahai V
J Natl Compr Canc Netw; 2022 Feb; 20(2):203-214. PubMed ID: 35130506
[TBL] [Abstract][Full Text] [Related]
2. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
3. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
4. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
5. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
6. Novel immunotherapy strategies for hepatobiliary cancers.
DeLeon TT; Zhou Y; Nagalo BM; Yokoda RT; Ahn DH; Ramanathan RK; Salomao MA; Aqel BA; Mahipal A; Bekaii-Saab TS; Borad MJ
Immunotherapy; 2018 Sep; 10(12):1077-1091. PubMed ID: 30185133
[TBL] [Abstract][Full Text] [Related]
7. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
8. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
[TBL] [Abstract][Full Text] [Related]
11. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
12. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
Giraud J; Chalopin D; Blanc JF; Saleh M
Front Immunol; 2021; 12():655697. PubMed ID: 33815418
[TBL] [Abstract][Full Text] [Related]
14. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
[TBL] [Abstract][Full Text] [Related]
15. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
Heinrich S; Craig AJ; Ma L; Heinrich B; Greten TF; Wang XW
J Hepatol; 2021 Mar; 74(3):700-715. PubMed ID: 33271159
[TBL] [Abstract][Full Text] [Related]
16. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy.
Erstad DJ; Fuchs BC; Tanabe KK
Cancer; 2018 Aug; 124(15):3084-3104. PubMed ID: 29663340
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of immune scores and immune microenvironment-related genes for hepatocellular carcinoma.
Ge PL; Li SF; Wang WW; Li CB; Fu YB; Feng ZK; Li L; Zhang G; Gao ZQ; Dang XW; Wu Y
Aging (Albany NY); 2020 Mar; 12(6):5479-5499. PubMed ID: 32213661
[TBL] [Abstract][Full Text] [Related]
19. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma.
Gao L; Xue J; Liu X; Cao L; Wang R; Lei L
Aging (Albany NY); 2021 Nov; 13(22):24866-24881. PubMed ID: 34839280
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures.
Lou X; Wang JJ; Wei YQ; He YJ; Jiang ZJ; Sun JJ
Med Oncol; 2021 Mar; 38(5):50. PubMed ID: 33786682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
